Curelab Veterinary Inc.
Join Us To Make Pets Live Longer
▼ keep reading ▼
Curelab Veterinary Inc.
Offering Platform
INTRODUCTION TO OUR COMPANY
The average life expectancy of dogs increased from 10.5 years to 11.8 years between 2002 and 2016, and the same trend was seen with cats. Veterinary preventative care (vaccines, de-wormers, etc.) and the humanization of pets have contributed to a longer life expectancy; pets are no longer “outside” animals but family members, often sleeping next to their parents. According to a survey, 28% of pet owners celebrate their dogs’ birthdays.
With increased health and owner attention (pet humanization), today’s pets are less likely to be killed by infectious diseases, trauma, or malnutrition; they are more likely to die from cancer.
Using the translational science developed by CureLab Oncology, CureLab Veterinary is developing advanced therapies to treat cancer and inflammatory diseases in pets, allowing pet owners to spend more time with their pets while supporting pet health and longevity.
ElenaVet™ p-62 DNA plasmid from CureLab Veterinary has been tested on a variety of animals and has demonstrated efficacy in reducing and attenuating proinflammatory mediators by changing the tumor microenvironment and by decreasing the tumor microenvironment. The process of chronic inflammation leads to cells becoming metaplastic and then cancerous. Many cancers can be treated with ElenaVet, as well as chronic inflammatory conditions in dogs and cats.
Cancer is now the #1 cause of death for dogs
operations summary
ElenaVet is a gene therapy that enhances the body's anticancer immune response.
ElenaVet is a plasmid (supercoiled circular DNA) in which we have inserted a gene-encoding protein p62/SQSTM1. Plasmids constitute a main trend in a new generation of biomedicine.
When injected into a patient, ElenaVet enters cells at the site of administering as well as in the bone marrow, and makes the cells it encodes produce p62 protein, which leads to multiple physiological outcomes.
ElenaVet also reduces chronic inflammation, which is a common characteristic of non-cancer diseases such as osteoarthritis, inflammatory bowel disease, chronic dermatologic issues, and age-associated declines. ElenaVet lowers pro-inflammatory cytokines and increases anti-inflammatory ones, thereby dramatically reducing overall inflammation. When a body is threatened by injury or illness, cells and tissues send out pro-inflammatory cytokines. Once the threat is over, anti-inflammatory cytokines calm the tissue down. If the body does not check the pro-inflammation process, there is a constant release of pro-inflammatory cytokines, causing chronic inflammation. Current anti-inflammatory treatments either target one specific proinflammatory cytokine or are highly toxic. ElenaVet has neither of these drawbacks. Instead of interfering with a particular cytokine, ElenaVet restores balance in the cells secreting them.
ElenaVet reduces chronic inflammation systemically because it can “rejuvenate” mesenchymal stem cells (MSCs). When a body is young, MSCs secrete mostly anti-inflammatory signals. When the body is old, MSCs secretome becomes predominantly pro-inflammatory. Also, in the bones of a young animal, MSCs differentiate into bone cells, osteoblasts, while in the old one, MSCs produce fat cells within the bone, adipocytes. ElenaVet turns the clock, making MSCs from an older animal act like they were from a young one.
Maximum Offering
$15,000,000
Minimum Offering
$500,000
Minimum Investment
$25,000
$15,000,000
Minimum Offering
$500,000
Minimum Investment
$25,000
$500,000
Minimum Investment
$25,000
$25,000
According to the Veterinary Cancer Society, cancer was the leading cause of death in 47% of dogs, especially those over the age of 10, and 32% of cats.
terms of the offering
$15,000,000
Minimum Offering: $500,000
Minimum Investment: $25,000
The Company is offering equity in the form of shares of Class A Common Stock (“Class A Shares”).
In the event of a Liquidation Event (as defined below), either voluntary or involuntary, the holders of Class C Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Company to the holders of Class A Common Stock and Class B Common Stock (the “Common Stock”) by reason of their ownership thereof, on a pari passu basis, an amount equal to $2,500,014 in aggregate and an amount equal to all declared but unpaid dividends on such share. If, upon the occurrence of such event, the assets and funds thus distributed among the holders of the Class C Preferred Stock shall be insufficient to permit the payment to such holders of the full aforesaid amount, then the entire assets and funds of the Company legally available for distribution to stockholders shall be distributed pro rata among the holders of the Class C Preferred Stock in proportion to the full amount each such holder is otherwise entitled to receive under this paragraph.
Upon completion of the distributions required by the foregoing paragraph, all of the remaining assets of the Company available for distribution to stockholders shall be distributed among the holders of Common Stock pro rata based on the number of shares of Common Stock held by each.
Notwithstanding the above, for purposes of determining the amount each holder of shares of Class C Preferred Stock is entitled to receive with respect to a Liquidation Event, each such holder of shares of Class C Preferred Stock shall be deemed to have converted (regardless of whether such holder actually converted) such holder’s shares of Preferred Stock one-to-one into shares of Class A Common Stock immediately prior to such Liquidation Event if, as a result of an actual conversion, such holder would receive, in the aggregate, an amount greater than the amount that would be distributed to such holder if such holder did not convert such Class C Preferred Stock into shares of Class A Common Stock. If any such holder shall be deemed to have converted shares of Class C Preferred Stock into Class A Common Stock pursuant to this paragraph, then such holder shall not be entitled to receive any distribution that would otherwise be made to holders of Class C Preferred Stock that have not converted (or have not been deemed to have converted) into shares of Class A Common Stock.
A “Liquidation Event” shall mean:
- (i) any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary;
- (ii) the acquisition of the Company by another entity by means of any reorganization, merger or consolidation (but excluding any reorganization, merger or consolidation effected exclusively for the purpose of changing the domicile of this Corporation), or any transaction or series of related transactions in which the Company’s stockholders of record as constituted immediately prior to such transaction or series of related transactions will, immediately after such transaction or series of related transactions (by virtue of securities issued in such transaction or series of related transactions) fail to hold at least 50% of the voting power of the resulting or surviving corporation (but excluding any sale of stock to investors for the principal purpose of raising capital);
- (iii) a sale, lease, transfer, or other disposition (whether by merger or otherwise), in a single transaction or any series of related transactions, by the Company of all or substantially all of the assets of the Company to any person or entity other than a wholly owned subsidiary of the Company; or
- (iv) the grant of an exclusive license to all or substantially all of the Company’s intellectual property in a single transaction or series of related transactions to any person or entity other than a wholly owned subsidiary of the Company.
The dividend rights and distributions per share shall be the same for Class A Common Stock, Class B Common Stock, and Class C Preferred Stock.
According to Global Market Insights, the cat and dog cancer global market will see double-digit market growth
Management Team
The Company is currently managed by seasoned business and sector professionals dedicated to the success of the Company and efficient execution of its planned operations.
Alexander
Shneider
Alexander Shneider
Founder, Director and Chairman of the Board
Over 25 years of biotech and entrepreneurial experience. Currently Senior Research Fellow of molecular biology at University of Ariel, Israel; editorial board member for journals Aging and Cell Cycle, advisor at We Fund Health. The past achievements and activities include but are not limited to drug development from concept to market authorization, patents in all major jurisdictions, advisory role for successful exits, consulting for Fortune 100 companies, establishing and leading international R&D consortia, senior authorship in papers and books.
Robert Devlin,
DVM, MBA
Robert Devlin, DVM, MBA
Director and President
Rob progressed from a practicing veterinarian to an executive director of veterinary science division to a seasoned VP of business development. Proven US and international track record in operations management, online and multichannel B2B and B2C sales within the animal health market, working with and developing US CMO vendors as well as distribution channels, spokespeople, and market KOLs, and establishing pricing models.
Ilya Lapshin
Ilya Lapshin
Director and General Counsel
20+ years of legal experience in a large New York law firm and two Massachusetts-based boutique firms helping startups and big corporate clients. Between a double major at MIT, Physics with Electrical Engineering and Math, and Boston University Law School, successful entrepreneurial and startup experience including a lucrative exit from a business, which Ilya started as a co-founder as soon as he came to the US.
Alexis Nahama, DVM
Alexis Nahama, DVM
Executive Vice President
Alexis Nahama, a veterinarian by training, has spent over 25 professional years in the fields of animal health and human life sciences. He is a seasoned executive with extensive experience in drug or device development across categories including pain, metabolic diseases and cancer. He has led complex business projects and teams as a senior executive in start-ups, large global organizations and publicly traded companies.
Trevor Olsen
Trevor Olsen
Controller
Over 10 years of experience in FP&A and Accounting. His experience has centered on providing innovative solutions through precise P&L reporting, accurate financial planning, and dynamic modeling and analysis.
Vlad Gabai, Ph.D.
Vlad Gabai, Ph.D.
VP of R&D
Over 30 years of successful discovery and development experience and problem-solving skills in R&D of anti-cancer drugs from bench to bedside. Over 80 papers, over 4,000 references. Past academic appointments with Boston University and Boston Biomedical Research Institute.
For 2023, it is estimated that $145 billion was spent on pets in the United States, with veterinary care and associated products accounting for $30.2 billion of that amount
so much more than what you see
Create an account to review the offering documents for our opportunity. Once registered, you will be able to:
- Access the Private Placement Memorandum, which outlines our company and gives greater detail about our offering;
- Access our SEC filing;
- View real time offering metrics of how far along we are in the offering process;
- View a timeline of your progress in the subscription process;
- Directly contact us with any questions;
- Easily upgrade your account to complete the subscription process.
When ready to invest, upgrade your account to:
- Complete the subscription documents;
- Upload accreditation documents, if applicable;
- Access instructions to transfer investment funds;
- Access company documents including Reports, Financials, and Supporting Documents;
- Access the Asset Portfolio, if applicable;
- View News articles written by the company;
- View and download documents associated with your account;
- View distributions to your account, if applicable.